37.85CHF-0.13%Mkt Cap: 1.25B CHFP/E: —Last update: 2026-06-01
PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceut…
Industry Peers
Drug Manufacturers - Specialty & Generic150.78BSEKP/E 166.4
58.93BTRY—
56.89BEURP/E 22.4
32.78BPLNP/E 21.4
23.20BUSDP/E 20.2
18.39BUSD—
16.21BUSDP/E 24.8
13.00BTRY—
Indicators:|
Key Statistics
Company
Market Cap1.25B CHF
Enterprise Value1.32B CHF
Revenue (TTM)389.33M CHF
Gross Profit66.53M CHF
Net Income (TTM)-21.17M CHF
Revenue/Share11.80 CHF
Last Price37.85 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees1.4K
CountryCH
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)33.51
PEG—
EV/EBITDA34.59
EV/Revenue3.38
P/S3.21
P/B3.97
EPS (TTM)-0.59
EPS (Forward)1.13
52W Range
18.6683% of range41.70
52W High41.70 CHF
52W Low18.66 CHF
Profitability
Gross Margin16.98%
Oper. Margin9.99%
EBITDA Margin9.78%
Profit Margin-5.40%
ROE-6.22%
ROA-2.56%
Growth
Revenue Growth10.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF77.51M CHF
CapEx (TTM)108.91M CHF
FCF Margin-11.25%
FCF Yield-3.51%
Net Debt66.77M CHF
Net Debt/EBITDA1.75
Balance Sheet
Debt/Equity0.38
Current Ratio1.74
Quick Ratio0.87
Book Value/Sh9.541 CHF
Cash/Share2.260 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 28, 2022
Pay DateMay 2, 2022
Analyst Consensus
Rating—
Target (Mean)35.59 CHF
Target Range25.20 CHF – 43.43 CHF
# Analysts6
Ownership
Shares Out.33.01M
Float12.96M
Insiders60.52%
Institutions20.27%
Technical
SMA 5034.03 (+11.2%)
SMA 20027.85 (+35.9%)
Beta1.02
S&P 52W Chg27.70%
Avg Vol (30d)73.69K
Avg Vol (10d)47.89K
Technical Indicators
RSI (14)55.8
MACD1.0182
MACD Signal1.3854
MACD Hist.-0.3673
BB Upper40.48 CHF
BB Middle38.42 CHF
BB Lower36.37 CHF
BB Width10.69%
ATR (14)1.584 CHF
Vol Ratio (20d)1.94x